Category : Search result: pharma inspections


Sudeep Pharma IPO: 22% GMP, Opens Nov 21

Sudeep Pharma's ₹95 crore IPO opens November 21 with strong grey market premium. Learn price band, dates, financials & investment details for this pharma ingredients maker.

European Pharma Stocks Rebound from AI Shift

European weight-loss drug makers surge as investors rotate capital from expensive AI stocks into healthcare. Zealand Pharma leads with a 20% weekly jump. Explore the market dynamics.

Purdue Pharma $7B Opioid Settlement Gets Court Nod

Federal judge approves Purdue Pharma's bankruptcy plan requiring Sackler family to pay $7 billion and surrender company ownership. Thousands of opioid victims to receive compensation in historic settlement.

Lincoln Pharma Aims for Rs 1000 Crore Revenue

Lincoln Pharmaceuticals Ltd announces ambitious plan to achieve Rs 1000 crore revenue within three years through strategic expansion and new product launches. Read more about their growth strategy.

Sun Pharma: US Tariff Clarity & Q2 FY26 Outlook

Sun Pharma investors await Q2 FY26 results with cautious optimism as US tariff clarity emerges. Discover how import duties and market dynamics could impact India's pharmaceutical giant.

AstraZeneca Q3 Profit Jumps 77% to $2.53 Billion

British-Swedish pharma giant AstraZeneca reports blockbuster Q3 results with profits surging 77% to $2.53 billion, driven by robust cancer drug sales and strategic US market expansion.

Navin Fluorine Shares Surge 22% in 3 Sessions

Discover why Navin Fluorine International shares skyrocketed 22% in just three trading sessions. Expert analysis reveals the key drivers behind this chemical sector powerhouse's impressive rally and what investors should watch next.

3 Hot Stocks: Grasim, Aurobindo Pharma, City Union Bank

Religare Broking's Ajit Mishra reveals 3 promising stocks for short-term gains. Discover technical analysis and price targets for Grasim, Aurobindo Pharma, and City Union Bank in this exclusive market insight.

Cipla Shares Fall 4% After Q2 Results

Cipla's stock faced significant pressure after Q2 FY2025 results revealed margin pressures despite revenue growth. Discover the key factors behind the 4% decline and what analysts are saying about the pharmaceutical giant's future prospects.

Page 3 of 4